home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 12/10/19

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - BeyondSpring's Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 Study 106 clinical trial design ...
BYSI - BeyondSpring's Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin's Mechanism of Action for CIN Accepted at American Society of Hematology's 2019 Annual Meeting

NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechanism of action for its lead asset, Pl...

BYSI - Sell-siders like Tela Bio in premarket analyst action

BeyondSpring (NASDAQ: BYSI ) initiated with Market Perform rating at Oppenheimer. More news on: BeyondSpring Inc., Centogene N.V., Curaleaf Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BYSI - BeyondSpring's Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s novel trial design for Study 103 with lead asset, Plinabu...
BYSI - BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resource...

BYSI - BeyondSpring: The Drop From The Capital Raise Offers A Good Entry Point

As of 1:30 pm on October 25, BeyondSpring (NASDAQ: BYSI ) was trading down 24% due to a public offering announced the day prior after close. The terms of the offering , announced this morning before market open, are for approximately 1.9M shares @ $13.50/share for gross proceeds of $25M. With...

BYSI - Midday Gainers / Losers

Gainers: Xunlei (NASDAQ: XNET ) +61% . Anika Therapeutics (NASDAQ: ANIK ) +36% . Reebonz Holding (NASDAQ: RBZ ) +25% . DMC Global (NASDAQ: BOOM ) +19% . AMAG Pharmaceuticals (NASDAQ: AMAG ) +16% . BJ's Restaurants (NASDAQ: BJRI ) +15% . Vipshop Holdings (NYSE: VIPS ) +15% . ResMed ...
BYSI - BUD, AMZN among premarket losers

Vocera Communications (NYSE: VCRA )  -27%  on Q3 earnings . More news on: Vocera Communications, Inc., Melinta Therapeutics, Inc., BeyondSpring Inc., Stocks on the move, Read more ...

BYSI - BeyondSpring down 21% premarket after pricing stock offering

Thinly traded micro cap BeyondSpring (NASDAQ: BYSI ) is down  21%  premarket on increased volume, albeit on turnover of only 22K shares, in reaction its public offering of ~1.9M ordinary shares at $13.50 per share. More news on: BeyondSpring Inc., Healthcare stocks news, Stocks...

BYSI - BeyondSpring Announces Pricing of Ordinary Shares

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...
Previous 10 Next 10